Senate Health Committee advances insulin cap, prenatal vitamin testing, CalAIM provider changes and other health bills

The California Senate Committee on Health on Oct. 27 advanced a package of health bills affecting millions of Californians, approving measures to cap insulin out‑of‑pocket costs, require testing and public disclosure for prenatal vitamins, strengthen Medi‑Cal contracting for community‑based providers under CalAIM, increase oversight of the state's Comprehensive Perinatal Services Program (CPSP), and limit automatic virtual‑card payment fees for dental providers.

Why it matters: The measures touch both clinical safety and access — the insulin cap addresses immediate affordability and life‑threatening medicine access, the prenatal‑vitamin measure aims to increase consumer transparency about heavy‑metal contaminants, and the CalAIM and CPSP items seek to preserve and expand services for Medi‑Cal enrollees and pregnant people who rely on state programs.

Insulin affordability (SB 40) Senate Bill 40, authored by Sen. Scott Wiener, would cap monthly out‑of‑pocket costs for insulin at $35 for health plans regulated at the state level. Wiener told the committee the bill is intended to mirror the $35 cap set for Medicare beneficiaries and to reduce life‑threatening insulin rationing. “If you don't take it, you will not be able to survive,” Wiener said.

Physicians and patient advocates testified in support, describing patients who skip or ration doses because of cost. Dr. Shagun Bhendesh, a diabetologist, told the committee she had “patients who ration their insulin to make it through the month,” and said the bill is “about dignity” and preventing avoidable suffering. Christine Falabel of the American Diabetes Association noted that California has millions living with diabetes and cited research showing one in six people with diabetes ration insulin because of cost.

Committee members discussed how SB 40 would coexist with California’s CalRx/CalRx‑type state manufacturing efforts; supporters and authors said the two approaches are complementary. The committee approved the bill as amended and referred it to the Appropriations Committee. Motion: do pass as amended and refer to Appropriations (mover: Sen. Richard Rubio). Final recorded committee tally on the day: 11–0 (aye 11, no 0). Outcome: approved by committee and referred for further fiscal review.

Prenatal‑vitamin testing and disclosure (SB 646) Sen. Sydney K. Weber‑Pearson presented SB 646, which would require manufacturers of prenatal vitamins sold in California to test products for specified toxic elements (including lead, arsenic, cadmium and mercury), to post batch‑level results online and to provide a QR code on packaging linking to test results and public information. The bill would require manufacturers to begin posting data on or before Jan. 1, 2027, under the version discussed in committee.

Weber‑Pearson argued that “there is a difference in products right now as far as the toxins that are there,” and said disclosure would let consumers make informed choices and incentivize manufacturers to reduce contaminants. Testimony for the bill included physicians and public‑health organizations: Dr. Danielle Vachon of ACOG District IX said, “These vitamins are a cornerstone of prenatal care” and that patients and clinicians need reliable information about product safety.

Industry witnesses — including the Council for Responsible Nutrition and the Consumer Healthcare Products Association — said they shared the goal of safety but raised technical and legal concerns. Trade witnesses noted that many trace metals come from agricultural sourcing and that California’s Proposition 65 already requires warnings when exposures exceed OEHHA thresholds. They proposed alternatives such as periodic finished‑product testing with submission to public health authorities or certificates of compliance in lieu of immediate batch disclosure.

Committee members and the author discussed language and technical fixes, including multilingual access to QR‑linked results and how disclosure would interact with Prop 65 and existing federal good manufacturing practices. The measure was approved by the committee as amended and referred on for fiscal review. Motion: do pass as amended and refer to the Environmental Quality Committee (mover: Sen. Richard Rubio). Final committee tally: 11–0 (aye 11, no 0). Outcome: approved by committee and referred to the next committee.

Medi‑Cal CalAIM: Enhanced Care Management and community supports (SB 324) Sen. Menjivar presented SB 324 to ease contracting barriers and administrative burdens that community‑based organizations (CBOs) face when participating in CalAIM initiatives such as Enhanced Care Management (ECM) and community supports. The bill would require plans to contract with available qualified community providers in a county, ask the Department of Health Care Services (DHCS) to standardize contracting templates, clarify the use of intermediary “community hub” models, and increase public reporting about providers of ECM and community supports.

Supporters said many community providers struggle to enroll with Medi‑Cal plans because of administrative burdens and competition from large, national for‑profit vendors. Kelly Bennett, CEO of Community Health Works, described contracting with multiple managed care plans and placing “over 600 individuals into housing” last year through CalAIM services but warned that varying plan requirements and low reimbursement rates threaten sustainability. Graciela Naya of Central California Asthma Collaborative testified that some CBOs waited up to a year to finalize contracts and, without capacity‑building funds, might not have been able to start services.

The committee accepted author amendments and moved the bill forward. Motion: do pass as amended and refer to Appropriations (mover: Sen. Menjivar). Final committee tally: 11–0 (aye 11, no 0). Outcome: approved by committee and referred to Appropriations.

Comprehensive Perinatal Services Program oversight (SB 228) Sen. Maria Cervantes presented SB 228 to implement recommendations from a 2024 California State Auditor report that found limited statewide data and uneven oversight of the Comprehensive Perinatal Services Program (CPSP), established by the Legislature in 1984. Cervantes said the program provides eligible pregnant and postpartum Medi‑Cal members services from conception to 60 days postpartum and seeks to reduce maternal and infant illness and death.

The auditor’s analysis found that available data was so limited it could assess CPSP usage for only about 14% of Medi‑Cal patients in 2022, and that only 45 of roughly 2,600 provider reviews in 2022 included an assessment of perinatal program services. The auditor also found that 22 of 61 local health jurisdictions did not complete statutorily required chart reviews.

SB 228 would clarify that DHCS is primarily responsible for CPSP delivery while collaborating with the California Department of Public Health (CDPH) on regulations, and would require a report to the Senate and Assembly health committees every three years describing which providers performed required reviews. The bill was presented with committee amendments and approved by the committee as amended. Motion: do pass as amended and refer to Appropriations (mover: Sen. Wiener). Final committee tally: 11–0 (aye 11, no 0). Outcome: approved by committee and referred to Appropriations.

Dental payment practices and virtual credit cards (SB 386) Sen. Limon presented SB 386, which responds to dental providers’ concerns about insurance plans routing payments through virtual credit‑card vendors that charge processing and redemption fees. The bill would require notice to providers of any fees associated with virtual‑card payments, require plans to offer an alternate non‑fee payment method, and permit providers to opt in to receiving virtual‑card payment methods rather than being defaulted into them.

Lawrence Gayden of the California Dental Association, sponsor of the bill, said providers have paid “up to 10% in fees just to access their payments owed to them by the plan.” The bill remained a collaborative effort among providers and plans; the California Association of Dental Plans said the committee amendments addressed its concerns and withdrew opposition.

The committee approved SB 386 as amended and referred it to Appropriations. Motion: do pass as amended and refer to Appropriations (mover: Sen. Rubio). Final committee tally: 11–0 (aye 11, no 0). Outcome: approved by committee and referred to Appropriations.

Votes at a glance (committee action summary) - SB 40 (Wiener): Cap insulin monthly copays at $35 for regulated plans; do pass as amended; referred to Appropriations. Mover: Sen. Rubio. Committee vote: 11–0. Outcome: approved and referred. - SB 646 (Weber‑Pearson): Require prenatal vitamin testing and public disclosure of toxic elements; do pass as amended; referred to Environmental Quality Committee. Mover: Sen. Rubio. Committee vote: 11–0. Outcome: approved and referred. - SB 324 (Menjivar): CalAIM contracting and administrative streamlining for community providers (ECM/community supports); do pass as amended; referred to Appropriations. Mover: Sen. Menjivar. Committee vote: 11–0. Outcome: approved and referred. - SB 228 (Cervantes): Strengthen oversight and reporting for the Comprehensive Perinatal Services Program; do pass as amended; referred to Appropriations. Mover: Sen. Wiener. Committee vote: 11–0. Outcome: approved and referred. - SB 386 (Limon): Require notice and opt‑in for virtual credit‑card payment fees for dental providers; do pass as amended; referred to Appropriations. Mover: Sen. Rubio. Committee vote: 11–0. Outcome: approved and referred. - Consent calendar: SB 223 and SB 246 were adopted on consent and referred; committee vote: 11–0.

What comes next: All measures that passed the committee were referred to Appropriations or the relevant fiscal/subject committee for further consideration. Several bills will require technical changes discussed in committee (for example, ensuring multilingual access to prenatal‑vitamin disclosure and clarifying interaction with Prop 65 and federal GMPs). Authors and stakeholders signaled continued negotiations on amendments ahead of fiscal hearings.

Sources and attributions: Quotes and testimony are drawn from the Senate Committee on Health hearing transcript for Oct. 27. Speakers quoted in this article include Senator Scott Wiener; Senator Sydney K. Weber‑Pearson; Senator Menjivar; Senator Maria Cervantes; Dr. Shagun Bhendesh (American Diabetes Association, scientific/medical director); Kelly Bennett (CEO, Community Health Works); and Dr. Danielle Vachon (ACOG District IX). All other speakers and organizations who recorded “me too” support or opposition during the hearing are listed in the committee record and transcript.